CD274 and acute myeloid leukemia: Furthermore, negative regulatory immune checkpoint molecules, such as PD‐L1, CTLA‐4, LAG‐3, TIM‐3, and IDO1, have all been demonstrated to be up‐regulated in AML and some of them may become promising therapeutic targets.7